Chemoprophylaxis against Mycobacterium avium complex infection induced in mice

M. avium complex (MAC) is one of the important causative agents of opportunistic infections among AIDS patients. Recent evidence showed that the entry of infection is through the gastrointestinal tract. In the present study, we compared the prophylactic effect of some antimicrobials against MAC infe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kekkaku 1999-09, Vol.74 (9), p.677-681
Hauptverfasser: Saito, H, Murakami, K, Kobayashi, K, Gidoh, M, Hidaka, T, Kwon, H H
Format: Artikel
Sprache:jpn
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 681
container_issue 9
container_start_page 677
container_title Kekkaku
container_volume 74
creator Saito, H
Murakami, K
Kobayashi, K
Gidoh, M
Hidaka, T
Kwon, H H
description M. avium complex (MAC) is one of the important causative agents of opportunistic infections among AIDS patients. Recent evidence showed that the entry of infection is through the gastrointestinal tract. In the present study, we compared the prophylactic effect of some antimicrobials against MAC infection induced in mice. Different groups of beige mice were fed with pellets containing 0.0067% (10 mg/kg) of KRM-1648, rifabutin (RFB) and clarithromycin (CAM). Seven days after the administration of drugs, the mice were infected with M. intracellular N-241 (5 x 10(8) CFU) orally, five times, every other day and killed one and 126 days after the last infection. The effect of drug was evaluated using the frequency and severity of gross lung lesions in the mice and by the total CFU recovered from the lungs and spleen. MAC infection was not likely to be established since there was no macroscopic evidence of lesion in organs and the recovery of cultures from lungs and spleen tested was negative, in 3 of 10 mice in the control group, 2 of 9 in the CAM group, 4 of 9 in the RFB group and 4 of 10 in the KRM group. These mice were excluded from the analysis of the study results. Thus, we examined 7 mice in the control group, 7 in the CAM group, 5 in the RFB group, and 6 in the KRM group. Tubercle-like lesions were observed in the lungs of all 7 mice in the control group (severity: 3+ in 5 mice; 4+ in 2 mice), in 5 of 7 mice (71%) in the CAM group (severity: 2+ in 1 mouse; 3+ in 4 mice), and in 4 of 5 mice (80%) in the RFB group (severity: 1+ in 1 mouse; 2+ in 1 mouse; 4+ in 2 mice), while only slight lesions (severity: 1+) were observed in 4 of 6 mice (67%) in the KRM group. There was no macroscopic evidence of lesion in spleen, liver and kidneys. The log CFU was determined at the next day of the completion of the last infection. The log CFU of the lungs was 2.49 and 2.28 in the control group and the CAM group, respectively. The bacteria were not recovered either from the lungs in the RFB and KRM groups, nor from the spleen in all the groups. The order of efficacy of the drugs on the basis of the CFUs recovered from the lungs and spleen in each group determined 126 days after the completion of the last infection was as follows; KRM > CAM > RFB in the lungs and KRM > CAM [symbol: see text] RFB in the spleen, although there was no significant difference among the three drugs (P < 0.05). However, the significantly preferable effect was obtained in the three drug groups as c
doi_str_mv 10.11400/kekkaku1923.74.677
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69217708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69217708</sourcerecordid><originalsourceid>FETCH-LOGICAL-j243t-21d2acae9afed73678a40ecc6387e58b7f9c193f75880c01012591216fc36de83</originalsourceid><addsrcrecordid>eNo1kD1PwzAYhD2AaFX6C5BQJraU13bijxFFfEkFFpgjx3lDTeIkxAlq_z2pKMvdDY9OpyPkisKG0gTgtsa6NvVENeMbmWyElGdkCcBYrKUUC7IOwRUAoBPgKrkgCwopT5miS_Ka7dB3_dD1u0Nj9i5E5tO4NozRy8F2hbEjDm7ykfk5qu183-A-cm2FdnRdO6dysljOHnln8ZKcV6YJuD75inw83L9nT_H27fE5u9vGXyzhY8xoyYw1qE2FpeRCKpMAWiu4kpiqQlbaUs0rmSoFFihQlmrKqKgsFyUqviI3f73z8u8Jw5h7Fyw2jWmxm0IuNKNSwhG8PoFT4bHM-8F5Mxzy_wf4LzezXyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69217708</pqid></control><display><type>article</type><title>Chemoprophylaxis against Mycobacterium avium complex infection induced in mice</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Saito, H ; Murakami, K ; Kobayashi, K ; Gidoh, M ; Hidaka, T ; Kwon, H H</creator><creatorcontrib>Saito, H ; Murakami, K ; Kobayashi, K ; Gidoh, M ; Hidaka, T ; Kwon, H H</creatorcontrib><description>M. avium complex (MAC) is one of the important causative agents of opportunistic infections among AIDS patients. Recent evidence showed that the entry of infection is through the gastrointestinal tract. In the present study, we compared the prophylactic effect of some antimicrobials against MAC infection induced in mice. Different groups of beige mice were fed with pellets containing 0.0067% (10 mg/kg) of KRM-1648, rifabutin (RFB) and clarithromycin (CAM). Seven days after the administration of drugs, the mice were infected with M. intracellular N-241 (5 x 10(8) CFU) orally, five times, every other day and killed one and 126 days after the last infection. The effect of drug was evaluated using the frequency and severity of gross lung lesions in the mice and by the total CFU recovered from the lungs and spleen. MAC infection was not likely to be established since there was no macroscopic evidence of lesion in organs and the recovery of cultures from lungs and spleen tested was negative, in 3 of 10 mice in the control group, 2 of 9 in the CAM group, 4 of 9 in the RFB group and 4 of 10 in the KRM group. These mice were excluded from the analysis of the study results. Thus, we examined 7 mice in the control group, 7 in the CAM group, 5 in the RFB group, and 6 in the KRM group. Tubercle-like lesions were observed in the lungs of all 7 mice in the control group (severity: 3+ in 5 mice; 4+ in 2 mice), in 5 of 7 mice (71%) in the CAM group (severity: 2+ in 1 mouse; 3+ in 4 mice), and in 4 of 5 mice (80%) in the RFB group (severity: 1+ in 1 mouse; 2+ in 1 mouse; 4+ in 2 mice), while only slight lesions (severity: 1+) were observed in 4 of 6 mice (67%) in the KRM group. There was no macroscopic evidence of lesion in spleen, liver and kidneys. The log CFU was determined at the next day of the completion of the last infection. The log CFU of the lungs was 2.49 and 2.28 in the control group and the CAM group, respectively. The bacteria were not recovered either from the lungs in the RFB and KRM groups, nor from the spleen in all the groups. The order of efficacy of the drugs on the basis of the CFUs recovered from the lungs and spleen in each group determined 126 days after the completion of the last infection was as follows; KRM &gt; CAM &gt; RFB in the lungs and KRM &gt; CAM [symbol: see text] RFB in the spleen, although there was no significant difference among the three drugs (P &lt; 0.05). However, the significantly preferable effect was obtained in the three drug groups as compared with the control group.</description><identifier>ISSN: 0022-9776</identifier><identifier>DOI: 10.11400/kekkaku1923.74.677</identifier><identifier>PMID: 10535281</identifier><language>jpn</language><publisher>Japan</publisher><subject>AIDS/HIV ; Animals ; Anti-Bacterial Agents - therapeutic use ; Antibiotics, Antitubercular - therapeutic use ; Clarithromycin - therapeutic use ; Female ; Mice ; Mycobacterium avium-intracellulare Infection - prevention &amp; control ; Rifabutin - therapeutic use ; Rifamycins - therapeutic use</subject><ispartof>Kekkaku, 1999-09, Vol.74 (9), p.677-681</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10535281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, H</creatorcontrib><creatorcontrib>Murakami, K</creatorcontrib><creatorcontrib>Kobayashi, K</creatorcontrib><creatorcontrib>Gidoh, M</creatorcontrib><creatorcontrib>Hidaka, T</creatorcontrib><creatorcontrib>Kwon, H H</creatorcontrib><title>Chemoprophylaxis against Mycobacterium avium complex infection induced in mice</title><title>Kekkaku</title><addtitle>Kekkaku</addtitle><description>M. avium complex (MAC) is one of the important causative agents of opportunistic infections among AIDS patients. Recent evidence showed that the entry of infection is through the gastrointestinal tract. In the present study, we compared the prophylactic effect of some antimicrobials against MAC infection induced in mice. Different groups of beige mice were fed with pellets containing 0.0067% (10 mg/kg) of KRM-1648, rifabutin (RFB) and clarithromycin (CAM). Seven days after the administration of drugs, the mice were infected with M. intracellular N-241 (5 x 10(8) CFU) orally, five times, every other day and killed one and 126 days after the last infection. The effect of drug was evaluated using the frequency and severity of gross lung lesions in the mice and by the total CFU recovered from the lungs and spleen. MAC infection was not likely to be established since there was no macroscopic evidence of lesion in organs and the recovery of cultures from lungs and spleen tested was negative, in 3 of 10 mice in the control group, 2 of 9 in the CAM group, 4 of 9 in the RFB group and 4 of 10 in the KRM group. These mice were excluded from the analysis of the study results. Thus, we examined 7 mice in the control group, 7 in the CAM group, 5 in the RFB group, and 6 in the KRM group. Tubercle-like lesions were observed in the lungs of all 7 mice in the control group (severity: 3+ in 5 mice; 4+ in 2 mice), in 5 of 7 mice (71%) in the CAM group (severity: 2+ in 1 mouse; 3+ in 4 mice), and in 4 of 5 mice (80%) in the RFB group (severity: 1+ in 1 mouse; 2+ in 1 mouse; 4+ in 2 mice), while only slight lesions (severity: 1+) were observed in 4 of 6 mice (67%) in the KRM group. There was no macroscopic evidence of lesion in spleen, liver and kidneys. The log CFU was determined at the next day of the completion of the last infection. The log CFU of the lungs was 2.49 and 2.28 in the control group and the CAM group, respectively. The bacteria were not recovered either from the lungs in the RFB and KRM groups, nor from the spleen in all the groups. The order of efficacy of the drugs on the basis of the CFUs recovered from the lungs and spleen in each group determined 126 days after the completion of the last infection was as follows; KRM &gt; CAM &gt; RFB in the lungs and KRM &gt; CAM [symbol: see text] RFB in the spleen, although there was no significant difference among the three drugs (P &lt; 0.05). However, the significantly preferable effect was obtained in the three drug groups as compared with the control group.</description><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics, Antitubercular - therapeutic use</subject><subject>Clarithromycin - therapeutic use</subject><subject>Female</subject><subject>Mice</subject><subject>Mycobacterium avium-intracellulare Infection - prevention &amp; control</subject><subject>Rifabutin - therapeutic use</subject><subject>Rifamycins - therapeutic use</subject><issn>0022-9776</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAYhD2AaFX6C5BQJraU13bijxFFfEkFFpgjx3lDTeIkxAlq_z2pKMvdDY9OpyPkisKG0gTgtsa6NvVENeMbmWyElGdkCcBYrKUUC7IOwRUAoBPgKrkgCwopT5miS_Ka7dB3_dD1u0Nj9i5E5tO4NozRy8F2hbEjDm7ykfk5qu183-A-cm2FdnRdO6dysljOHnln8ZKcV6YJuD75inw83L9nT_H27fE5u9vGXyzhY8xoyYw1qE2FpeRCKpMAWiu4kpiqQlbaUs0rmSoFFihQlmrKqKgsFyUqviI3f73z8u8Jw5h7Fyw2jWmxm0IuNKNSwhG8PoFT4bHM-8F5Mxzy_wf4LzezXyQ</recordid><startdate>199909</startdate><enddate>199909</enddate><creator>Saito, H</creator><creator>Murakami, K</creator><creator>Kobayashi, K</creator><creator>Gidoh, M</creator><creator>Hidaka, T</creator><creator>Kwon, H H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199909</creationdate><title>Chemoprophylaxis against Mycobacterium avium complex infection induced in mice</title><author>Saito, H ; Murakami, K ; Kobayashi, K ; Gidoh, M ; Hidaka, T ; Kwon, H H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j243t-21d2acae9afed73678a40ecc6387e58b7f9c193f75880c01012591216fc36de83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1999</creationdate><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics, Antitubercular - therapeutic use</topic><topic>Clarithromycin - therapeutic use</topic><topic>Female</topic><topic>Mice</topic><topic>Mycobacterium avium-intracellulare Infection - prevention &amp; control</topic><topic>Rifabutin - therapeutic use</topic><topic>Rifamycins - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Saito, H</creatorcontrib><creatorcontrib>Murakami, K</creatorcontrib><creatorcontrib>Kobayashi, K</creatorcontrib><creatorcontrib>Gidoh, M</creatorcontrib><creatorcontrib>Hidaka, T</creatorcontrib><creatorcontrib>Kwon, H H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Kekkaku</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, H</au><au>Murakami, K</au><au>Kobayashi, K</au><au>Gidoh, M</au><au>Hidaka, T</au><au>Kwon, H H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemoprophylaxis against Mycobacterium avium complex infection induced in mice</atitle><jtitle>Kekkaku</jtitle><addtitle>Kekkaku</addtitle><date>1999-09</date><risdate>1999</risdate><volume>74</volume><issue>9</issue><spage>677</spage><epage>681</epage><pages>677-681</pages><issn>0022-9776</issn><abstract>M. avium complex (MAC) is one of the important causative agents of opportunistic infections among AIDS patients. Recent evidence showed that the entry of infection is through the gastrointestinal tract. In the present study, we compared the prophylactic effect of some antimicrobials against MAC infection induced in mice. Different groups of beige mice were fed with pellets containing 0.0067% (10 mg/kg) of KRM-1648, rifabutin (RFB) and clarithromycin (CAM). Seven days after the administration of drugs, the mice were infected with M. intracellular N-241 (5 x 10(8) CFU) orally, five times, every other day and killed one and 126 days after the last infection. The effect of drug was evaluated using the frequency and severity of gross lung lesions in the mice and by the total CFU recovered from the lungs and spleen. MAC infection was not likely to be established since there was no macroscopic evidence of lesion in organs and the recovery of cultures from lungs and spleen tested was negative, in 3 of 10 mice in the control group, 2 of 9 in the CAM group, 4 of 9 in the RFB group and 4 of 10 in the KRM group. These mice were excluded from the analysis of the study results. Thus, we examined 7 mice in the control group, 7 in the CAM group, 5 in the RFB group, and 6 in the KRM group. Tubercle-like lesions were observed in the lungs of all 7 mice in the control group (severity: 3+ in 5 mice; 4+ in 2 mice), in 5 of 7 mice (71%) in the CAM group (severity: 2+ in 1 mouse; 3+ in 4 mice), and in 4 of 5 mice (80%) in the RFB group (severity: 1+ in 1 mouse; 2+ in 1 mouse; 4+ in 2 mice), while only slight lesions (severity: 1+) were observed in 4 of 6 mice (67%) in the KRM group. There was no macroscopic evidence of lesion in spleen, liver and kidneys. The log CFU was determined at the next day of the completion of the last infection. The log CFU of the lungs was 2.49 and 2.28 in the control group and the CAM group, respectively. The bacteria were not recovered either from the lungs in the RFB and KRM groups, nor from the spleen in all the groups. The order of efficacy of the drugs on the basis of the CFUs recovered from the lungs and spleen in each group determined 126 days after the completion of the last infection was as follows; KRM &gt; CAM &gt; RFB in the lungs and KRM &gt; CAM [symbol: see text] RFB in the spleen, although there was no significant difference among the three drugs (P &lt; 0.05). However, the significantly preferable effect was obtained in the three drug groups as compared with the control group.</abstract><cop>Japan</cop><pmid>10535281</pmid><doi>10.11400/kekkaku1923.74.677</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-9776
ispartof Kekkaku, 1999-09, Vol.74 (9), p.677-681
issn 0022-9776
language jpn
recordid cdi_proquest_miscellaneous_69217708
source J-STAGE Free; MEDLINE
subjects AIDS/HIV
Animals
Anti-Bacterial Agents - therapeutic use
Antibiotics, Antitubercular - therapeutic use
Clarithromycin - therapeutic use
Female
Mice
Mycobacterium avium-intracellulare Infection - prevention & control
Rifabutin - therapeutic use
Rifamycins - therapeutic use
title Chemoprophylaxis against Mycobacterium avium complex infection induced in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T03%3A55%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemoprophylaxis%20against%20Mycobacterium%20avium%20complex%20infection%20induced%20in%20mice&rft.jtitle=Kekkaku&rft.au=Saito,%20H&rft.date=1999-09&rft.volume=74&rft.issue=9&rft.spage=677&rft.epage=681&rft.pages=677-681&rft.issn=0022-9776&rft_id=info:doi/10.11400/kekkaku1923.74.677&rft_dat=%3Cproquest_pubme%3E69217708%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69217708&rft_id=info:pmid/10535281&rfr_iscdi=true